Corrigendum to “Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]
Corrigendum to “Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]
Nonko Pehlivanov, Wan‐Long Chuang, Oliver Lenz, G.K. Kim et al.
Journal
JHEP Reports
Topics
Hepatitis B Virus Studies
article
Corrigendum to “Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]
Nonko Pehlivanov, Wan‐Long Chuang, Oliver Lenz, G.K. Kim, Thierry Verbinnen, John Jezorwski, Michael Biermer, Ewa Janczewska, Cheng‐Yuan Peng, Adam Bakala, Ronald Kalmeijer, Zacharias Anastasiou, Yasuhiro Asahina, Thomas N. Kakuda, Edward Gane, Maria Hlebowicz, Ting‐Tsung Chang, Tetsuo Takehara
article en
Abstract
No abstract available for this paper.
Publication Tag
JHEP ReportsVol. 7(12)
Institutions
Johnson & Johnson (United States) (US), Janssen (Belgium) (BE), University of Auckland (NZ), China Medical University (TW), Kaohsiung Medical University Chung-Ho Memorial Hospital (TW), IQVIA (United States) (US), China Medical University Hospital (TW), Johnson & Johnson (Australia) (AU), National Cheng Kung University Hospital (TW), University of Warmia and Mazury in Olsztyn (PL), The University of Tokyo (JP), The University of Osaka (JP)